Aptuit And Chiesi Collaborate To Treat Idiopathic Pulmonary Fibrosis

News   Jan 05, 2017 | Original story from Aptuit

 
Aptuit And Chiesi Collaborate To Treat Idiopathic Pulmonary Fibrosis
 
 
 

RELATED ARTICLES

Multidisciplinary Study Suggests New Strategy for Drug Discovery

News

A joint industry/academia study of a cancer target protein reveals unusual relation between binding site flexibility and drug-target lifetime. The results, , suggest a new strategy for drug discovery.

READ MORE

Concept Life Sciences appoints New Group Programme Manager and US Head of Sales

News

Key leadership appointments support integration of the Group and expansion in the US market.

READ MORE

Batavia Biosciences Teams Up with International Consortium to Support Polio Eradication

News

Batavia Biosciences announces its partnership with an international consortium coordinated by PATH aiming to develop and manufacture safer novel oral poliovirus vaccines (nOPV).

READ MORE

 

Comments | 1 ADD COMMENT

Ana Aitawa | Oct 03, 2017

The global idiopathic pulmonary fibrosis treatment market expected to reach US$ 3.5 billion by 2021, growing at CAGR 14.4% over the forecast period 2017-2021, owing to increasing drug prices and rapid approval of new treatments. Visit Idiopathic Pulmonary Fibrosis (IPF) Treatment Market by Treatment Type – Pharmacological Treatment (Pirfenidone (Esbriet), Nintedanib (Ofev), Generic Pirfenidone); Non-pharmacological Treatment (Oxygen Therapy, Pulmonary Rehabilitation, Mechanical Ventilation, Lung Transplantation, Other Non-Pharmacological Treatment); Patients by Disease Severity (Mild, Moderate, Severe); Drug Pipeline Analysis (AEOL-10150, Lebrikizumab, Tipelukast, Tralokinumab, FG-3019, Simtuzumab, BMS-986020, AF-219, SAR156597, BG00011, PRM-151, PBI-4050) at https://www.ihealthcareanalyst.com/report/idiopathic-pulmonary-fibrosis-treatment-market/


To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE